DPY19L3

Across TCGA pan-cancer cohorts, DPY19L3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DPY19L3 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DPY19L3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DPY19L3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, UCEC, and LUAD are the cancer types where DPY19L3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.063	0.582	<.001	19	view →
UCEC	DFS	Median	II,III,IV	0.926	0.434	.018	18	view →
LUAD	DFS	Median	All	0.306	0.819	<.001	17	view →
LUSC	OS	Median	All	0.174	0.729	<.001	6	view →
COAD	OS	Median	All	0.565	0.871	.019	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DPY19L3–BLCA (OS)

Open the BLCA breakdown →